MorphoSys and Incyte have announced that tafasitamab-cxix, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines® (NCCN Guidelines®) in Oncology for B-Cell Lymphomas. Specifically, the NCCN Guidelines in…
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with medical oncologist Yüksel Ürün, MD,…
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with medical oncologist Yüksel Ürün, MD,…
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with medical oncologist Yüksel Ürün, MD,…
The annual Global Cardio-Oncology Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology Society, the only multidisciplinary p…
At the 2024 World Conference on Lung Cancer, more than 7,000 clinicians and scientists gathered in San Diego in celebration of the 50th anniversary of…
An analysis of pancreatic cancer in young adults (aged 15–39) has found that although there is an increase in incidence, the mortality rate remains stable.…
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2…
Vered Stearns, MD, is the Director for Translational Breast Cancer Research in the Department of Hematology and Medical Oncology at Sandra and Edward Meyer Cancer…
To be presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting, a phase II study by Riess et al investigating the IO102-IO103 vaccine…
Beyond the physical toll of the disease and its treatments, cancer often presents a host of legal and social issues that can significantly worsen a…
